PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD.
On June 13, 2018, Protagenic Therapeutics, Inc. (the “Company”) issued a letter to its stockholders reporting on the Company’s developmental progress toward filing an FDA Investigational New Drug (IND) application for its three targeted clinical indications. The stockholder letter, as well as the cover page to the Company’s annual report, are furnished as Exhibit 99.1 hereto.
The information in this Form 8-K (including the Exhibit) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by referenced in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referenced in such a filing.
Item 9.01. Financial Statements and Exhibits.
Protagenic Therapeutics, Inc.new ExhibitEX-99.1 2 ex99-1.htm The Face of an Epidemic Source: Publicly Available Government Records Deaths from prescription Opiates and Heroin is the fastest-growing major cause of death in the U.S.,…To view the full exhibit click
About PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX)
Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.